Lanreotide injection
Products billed under this code include Lanreotide Acetate, Somatuline Depot.
Payment limit per 1 MG, by effective quarter, 1Q21 to 4Q26. Gaps mean the code was not in that quarter’s file, or CMS gave no payment limit.Products billed under this code include Lanreotide Acetate, Somatuline Depot.
Payment limit per 1 MG, by effective quarter, 1Q21 to 4Q26. Gaps mean the code was not in that quarter’s file, or CMS gave no payment limit.From the 4Q26 NDC–HCPCS crosswalk. “Limit / pkg” is the 4Q26 payment limit times the billing units in one package.
| Product | Labeler | NDC | Units / pkg | Limit / pkg |
|---|---|---|---|---|
| Lanreotide Acetate | Cipla USA, Inc. | 69097-0906-67 | 120 | $5,002.56 |
| Somatuline Depot | Ipsen Biopharmaceuticals, Inc. | 15054-1060-04 | 60 | $2,501.28 |
| Somatuline Depot | Ipsen Biopharmaceuticals, Inc. | 15054-1090-04 | 90 | $3,751.92 |
| Somatuline Depot | Ipsen Biopharmaceuticals, Inc. | 15054-1120-04 | 120 | $5,002.56 |
| Quarter | Payment limit | Change | Billing unit | Description | Source file |
|---|---|---|---|---|---|
| 4Q26 | $41.688 | +$4.26 | 1 MG | Lanreotide injection | v1, posted September 17, 2026 |
| 3Q26 | $37.428 | +$1.706 | 1 MG | Lanreotide injection | v1, posted September 15, 2026 |
| 2Q26 | $35.722 | +$0.334 | 1 MG | Lanreotide injection | v1, posted September 15, 2026 |
| 1Q26 | $35.388 | +$1.342 | 1 MG | Lanreotide injection | v1, posted September 15, 2026 |
| 4Q25 | $34.046 | −$2.611 | 1 MG | Lanreotide injection | v1, posted September 8, 2026 |
| 3Q25 | $36.657 | −$2.922 | 1 MG | Lanreotide injection | v1, posted March 10, 2026 |
| 2Q25 | $39.579 | −$5.438 | 1 MG | Lanreotide injection | v1, posted March 10, 2026 |
| 1Q25 | $45.017 | −$4.954 | 1 MG | Lanreotide injection | v1, posted December 19, 2025 |
| 4Q24 | $49.971 | −$0.054 | 1 MG | Lanreotide injection | v1, posted June 11, 2025 |
| 3Q24 | $50.025 | +$2.024 | 1 MG | Lanreotide injection | v1, posted June 11, 2025 |
| 2Q24 | $48.001 | −$0.442 | 1 MG | Lanreotide injection | v1, posted March 11, 2025 |
| 1Q24 | $48.443 | −$2.713 | 1 MG | Lanreotide injection | v1, posted December 19, 2024 |
| 4Q23 | $51.156 | −$3.026 | 1 MG | Lanreotide injection | v1, posted October 10, 2024 |
| 3Q23 | $54.182 | −$3.236 | 1 MG | Lanreotide injection | v1, posted June 5, 2024 |
| 2Q23 | $57.418 | −$4.142 | 1 MG | Lanreotide injection | v1, posted February 23, 2024 |
| 1Q23 | $61.56 | −$2.116 | 1 MG | Lanreotide injection | v1, posted December 6, 2023 |
| 4Q22 | $63.676 | −$2.296 | 1 MG | Lanreotide injection | v1, posted June 22, 2023 |
| 3Q22 | $65.972 | +$0.966 | 1 MG | Lanreotide injection | v1, posted June 9, 2023 |
| 2Q22 | $65.006 | −$1.177 | 1 MG | Lanreotide injection | v1, posted December 14, 2022 |
| 1Q22 | $66.183 | −$1.455 | 1 MG | Lanreotide injection | v1, posted June 8, 2022 |
| 4Q21 | $67.638 | −$0.866 | 1 MG | Lanreotide injection | v1, posted June 2, 2022 |
| 3Q21 | $68.504 | +$1.779 | 1 MG | Lanreotide injection | v1, posted June 2, 2022 |
| 2Q21 | $66.725 | −$1.738 | 1 MG | Lanreotide injection | v1, posted March 1, 2022 |
| 1Q21 | $68.463 | – | 1 MG | Lanreotide injection | v1, posted December 10, 2021 |
“Change” is the difference from the previous quarter, shown only when both quarters have a payment limit and the billing unit is the same. “vs. last quarter” and “vs. a year ago” follow the same rule.